Beam Therapeutics Inc.
BEAM Healthcare Biotechnology
Beam Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $139.7 million, up 120.0% from fiscal 2024. In the quarter to June 2026, revenue fell 94.2%, EPS fell 18.0% and free cash flow grew 13.9%, each against the same quarter a year earlier.
Follow BEAM
Beam Therapeutics Inc. (BEAM) Altman Z-score
Beam Therapeutics Inc.'s Altman Z-score for fiscal 2025 is 5.41, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 5.41 | 4.52 |
| FY2024 | 0.89 | (1.29) |
| FY2023 | 2.18 | 0.59 |
| FY2022 | 1.59 | (2.44) |
| FY2021 | 4.03 | (5.42) |
| FY2020 | 9.45 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.79 | — | 0.95 | |
| Retained earnings / total assets | (1.11) | — | −1.55 | |
| EBIT / total assets | (0.26) | — | −0.85 | |
| Market value of equity / total liabilities | 11.29 | — | 6.77 | |
| Sales / total assets | 0.09 | — | 0.09 | |
| Altman Z-score | Safe zone | 5.41 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 5.19 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| NAMS NewAmsterdam Pharma Company N.V. compare | 27.6× |
| ADMA ADMA Biologics Inc compare | 20.0× |
| BEAM Beam Therapeutics Inc. | 5.4× |
| NRIX Nurix Therapeutics, Inc. compare | 3.8× |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −0.2× |
| SLS SELLAS Life Sciences Group, Inc. compare | −16.8× |
| PGEN Precigen, Inc. compare | −16.9× |
| MBX MBX Biosciences, Inc. compare | — |
| DYN Dyne Therapeutics, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets